Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study.

antiretroviral therapy cerebrospinal fluid glial fibrillary acidic protein neurofilament light chain neurological injury

Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
22 Aug 2024
Historique:
received: 03 03 2024
revised: 29 06 2024
accepted: 20 08 2024
medline: 22 8 2024
pubmed: 22 8 2024
entrez: 22 8 2024
Statut: aheadofprint

Résumé

It is debated whether central nervous system involvement begins during acute HIV infection in persons without meningitis/encephalitis and if specific antiretroviral drugs or combinations would be beneficial. Neurologically asymptomatic participants enrolled in a randomized and controlled study comparing three combination antiretroviral regimens (tenofovir alafenamide/emtricitabine plus dolutegravir, darunavir or both) during primary HIV infection were enrolled. Serum and cerebrospinal fluid (CSF) were collected at baseline, 12 and 48 (serum only) weeks after treatment initiation. Single Molecule Array was used to measure neurofilament light chain (NFL), total tau protein (Tau), Brain-Derived Neurotrophic Factor (BDNF), Glial Fibrillary Acidic Protein (GFAP), Ubiquitin C-terminal Hydrolase (UCH-L1). We assessed the longitudinal change in biomarkers over time as well as the change in the prevalence of serum NFL concentrations above previously published age-adjusted cut-offs (7 pg/mL if 5-18 years, 10 pg/mL if 18-51 years, 15 pg/mL if 51-61 years, 20 pg/mL if 61-70 years and 35 pg/mL if >70 years). Serum was available from 47 participants at all time points while CSF was in 13 and 7 participants (baseline/W12). We observed a significant direct serum-to-CSF correlation for NFL (rho = 0.692, p = 0.009), GFAP (rho = 0.659, p = 0.014) and BDNF (rho = 0.587, p = 0.045). Serum (rho = 0.560, p = 0.046) and CSF NFL (rho = 0.582, p = 0.037) concentrations were directly associated with CSF HIV RNA levels. We observed a significant decrease over time in serum NFL (p = 0.006) and GFAP (p = 0.006) but not in the other biomarkers. No significant difference was observed among the treatment arms. At baseline, serum and CSF age-adjusted NFL levels were above age-adjusted cut-offs in 23 (48.9%) and 4 participants (30.8%); considering serum NFL, this proportion was lower at weeks 12 (31.9%, p = 0.057) and 48 (27.7%, p = 0.13). A relevant proportion of neurologically asymptomatic participants had abnormal CSF and serum NFL levels during primary HIV infection. NFL and GFAP decreased in serum following combination antiretroviral therapy without significant differences among the treatment arms.

Identifiants

pubmed: 39171829
pii: 7738665
doi: 10.1093/brain/awae271
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Andrea Calcagno (A)

Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, 10149 Turin, Italy.

Jessica Cusato (J)

Laboratory of Clinical Pharmacology and Pharmacogenetics, University of Turin, 10149 Turin, Italy.

Paola Cinque (P)

Infectious Diseases Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.

Giulia Marchetti (G)

Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, Italy.
School of Medicine and Surgery, University of Milan, 20122 Milan, Italy.

Davide Bernasconi (D)

Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4 School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
Department of Clinical Research and Innovation, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.

Mattia Trunfio (M)

Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, 10149 Turin, Italy.
HIV Neurobehavioral Research Program, Department of Psychiatry, University of California, UCSD, La Jolla, CA 92093-0021, USA.

Elena Bruzzesi (E)

Infectious Diseases Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.

Stefano Rusconi (S)

School of Medicine and Surgery, University of Milan, 20122 Milan, Italy.
SC Malattie Infettive, Ospedale di Legnano, ASST Ovest Milanese, 20025 Legnano, Italy.

Arianna Gabrieli (A)

Dipartimento di Scienze Biomediche e Cliniche (DIBIC), 20157 Milan, Italy.

Antonio Muscatello (A)

Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Andrea Antinori (A)

Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy.

Diego Ripamonti (D)

Infectious Disease Unit, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy.

Roberto Gulminetti (R)

Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.

Miriam Antonucci (M)

SCDU Infectious Diseases, Amedeo di Savoia Hospital, ASL Città di Torino, 10149 Turin, Italy.

Silvia Nozza (S)

Infectious Diseases Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.

Classifications MeSH